YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST: CLINICAL CARDIOLOGY
334 - IMPORTANT QUESTIONS REQUIRING ANSWERS - ARRHYTHMIA CHALLENGES
Saturday, October 26, 2024
11:15 AM – 11:30 AM PT
Room: 211
• “Lost in translation”- Challenging the guidelines with imperfect evidence I. Renaissance for class 1c anti arrhythmia in CAD & LV dysfunction? 69 yr. female with well controlled symptomatic PAF on flecainide for 5 years had recent ACS and PCI for LAD/normal EF-“Renaissance” for Class 1c anti-arrhythmic in CAD & LV dysfunction? II. Guidelines recommend CRT BUT does CRT actually benefit patients with QRS <150 msec? 73 yr. female with symptomatic HFrEF and LBBB QRS 130 msec. III. ICD & preventing sudden death-The unrealistic expectations of “Doc & patient” on benefits vs. harm IV. 75 yr. female with a non-ischemic DCM/AF, GDMT and EF 33%
• “I do not want a stroke” - the water still is “muddy” I. Dialysis dependent renal failure and atrial fibrillation – equipoise for DOAC, Warfarin or nothing? II. “Cryptogenic embolic MCA stroke” with sinus rhythm and normal echo in my 49 yr. female III. “I need help!” - Device detected asymptomatic AF & OAC - the hazards, guarantees and natural history of SCAF
Disclosure(s):
William F. McIntyre, MD: Atricure: Consultant/Advisory Board (Ongoing); iRhythm: Speaker/Honoraria (Ongoing); Trimedics: consulting (Ongoing), research grants (Ongoing)